A worldwide outbreak of severe acute respiratory syndrome emerged in 2019 and developed in a pandemic of COVID-19. This respiratory βeta-coronavirus is characterized by the severity of its complications, that is acute pulmonary inflammation, pneumonia, lung fibrosis and organ dysfunction, ultimately inducing fatality. Scientists worldwide have focused on finding medication and vaccine for fighting the viral disease, yet its high transmission and mutagenicity renders international efforts challenging. Drugs may also not be the only approach. Previous animal studies on pulmonary infectious diseases and a recent case report of a COVID-19 patient with comorbidities demonstrated the mitigation of inflammatory processes addressed with Infrared Photobiomodulation therapy (IR-PBMT). Here, we report the use of PBMT at different wavelengths and treatment parameters on two patients with acute infectious respiratory syndrome, who may represent early COVID-19 patients in the United Kingdom and France. This case report's dissemination to the broader scientific community is of interest for PBMT was successfully applied according to clinical presentation, double-blind to COVID-19 diagnosis. Two females, mean age 60, manifested signs of acute respiratory infection at the end of 2019. According to the CARE checklist, we retrospectively collected data from patients and screening laboratories to ascertain epidemiological and symptomatologic aspects and reported clinical, laboratory, radiological, scanner and immunology findings. Both patients experienced at the onset of illness fever, burning feeling in the throat, throbbing cough, myalgia, severe fatigue, headache, loss of taste, dyspnoea and pneumonia signs. Symptoms aggravated into chest tightness and respiratory difficulties. One patient experienced diarrhoea and cutaneous manifestations. Patients received PBMT with non-coherent red light (RL) 630 nm and 660 nm, significantly improving oxygenation, respiratory function and inflammatory syndrome, avoiding emergency care. This case report demonstrates the potential clinical value of PBMT in mitigating inflammation, improving respiratory distress and oxygenation at early stages of COVID-19 and in other infectious lung diseases, preventing viral infections complications. It also expands our knowledge on RL and its positive effects